Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
82.47
+2.23 (2.78%)
At close: Jan 29, 2026, 4:00 PM EST
82.48
+0.01 (0.01%)
After-hours: Jan 29, 2026, 4:00 PM EST
Bright Minds Biosciences Employees
Bright Minds Biosciences had 26 employees as of September 30, 2025. The number of employees increased by 25 or 2,500.00% compared to the previous year.
Employees
26
Change (1Y)
25
Growth (1Y)
2,500.00%
Revenue / Employee
n/a
Profits / Employee
-$337,686
Market Cap
790.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 26 | 25 | 2,500.00% |
| Sep 30, 2024 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Valneva SE | 713 |
| Arvinas | 430 |
| Geron | 229 |
| Prime Medicine | 214 |
| Omeros | 202 |
| Janux Therapeutics | 81 |
| Nektar Therapeutics | 61 |
DRUG News
- 20 days ago - Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - GlobeNewsWire
- 21 days ago - Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - GlobeNewsWire
- 22 days ago - Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
- 23 days ago - Bright Minds Biosciences Announces Launch of US$100 Million Public Offering - GlobeNewsWire
- 23 days ago - New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Benzinga
- 23 days ago - Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) - GlobeNewsWire
- 24 days ago - Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - GlobeNewsWire
- 2 months ago - Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting - GlobeNewsWire